BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV

SAN RAFAEL, Calif., May 8, 2024

An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

About BioMarin
Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.

Contacts:
Investors	Media ARIVA.DE Börsen-Geflüster Werbung Weiter aufwärts? Kurzfristig positionieren in BioMarin Pharmaceutical ME4CET Ask: 0,76 Hebel: 6,44 mit moderatem Hebel Zum Produkt Morgan Stanley Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: ME4CET,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen. Kurse BioMarin Pharmaceutical 77,53 $ +0,73%
Traci McCarty	Marni Kottle
BioMarin Pharmaceutical Inc.	BioMarin Pharmaceutical Inc.
(415) 455-7558	(650) 374-2803

View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-present-at-the-bofa-securities-2024-health-care-conference-on-wednesday-may-15-at-1000am-pt--100pm-et-in-las-vegas-nv-302139003.html

SOURCE BioMarin Pharmaceutical Inc.